CELL INTELLIGENCE · 肿瘤细胞治疗研究

TIL（肿瘤浸润淋巴细胞）与乳腺放疗：国际免疫肿瘤生物标志物工作组展望

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

TIL 治疗进展：拓展黑色素瘤之外的视野

Advances in TIL therapy: Expanding the horizons beyond melanoma.

TIL（肿瘤浸润淋巴细胞）与早期乳腺癌术前部分乳腺照射：来自前瞻性 PAPBI 队列的见解

Tumor-Infiltrating Lymphocytes and Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer: Insights From the Prospective PAPBI Cohort.

在这一接受术前部分乳腺照射的早期乳腺癌患者队列中，纵向评估显示 RT 后 sTILs 变化极小。在达到 pCR 的患者中，我们观察到其基线 sTILs 显著高于未达到 pCR 的患者。

从疫苗接种部位皮肤活检中分离肿瘤新抗原特异性 CD8+ TCR

Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site.

乳腺癌免疫治疗：从检查点抑制到新兴细胞治疗

Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies.

TIL（肿瘤浸润淋巴细胞）动态变化作为 luminal 型乳腺癌新辅助治疗反应的生物标志物

Tumor-Infiltrating lymphocyte dynamics as biomarkers of neoadjuvant treatment response in luminal breast cancer.

理解 TILs：胃食管癌 TIL（肿瘤浸润淋巴细胞）形态学评估建议——代表国际免疫肿瘤生物标志物工作组报告

Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma: A report on beh

乳腺癌与女性生殖道肿瘤中的 TIL（肿瘤浸润淋巴细胞）：被忽视的潜力与未探索的前沿

Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers.

基于 TIL 的疗法在个体化免疫治疗中显示出潜力，尤其是在复发、难治性卵巢癌中。对较罕见妇科肿瘤的研究有限，阻碍了更广泛的临床应用。

剂量密集剂量强化新辅助化疗治疗的三阴性乳腺癌患者中治疗后基质 TIL（肿瘤浸润淋巴细胞）与生存的负相关关系

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treate